| 1 |
32195541 | ACE-domain selectivity extends beyond direct interacting residues at the active site. | 2020 Apr 17 |
1 |
| 2 |
30283782 | Neprilysin Inhibitors and Bradykinin. | 2018 |
1 |
| 3 |
30372620 | Molecular Basis for Multiple Omapatrilat Binding Sites within the ACE C-Domain: Implications for Drug Design. | 2018 Nov 21 |
2 |
| 4 |
28419972 | Neprilysin inhibitors: A new hope to halt the diabetic cardiovascular and renal complications? | 2017 Jun |
3 |
| 5 |
26209000 | Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact. | 2015 Sep |
1 |
| 6 |
23927843 | Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. | 2013 Oct |
2 |
| 7 |
21853869 | The natriuretic peptide neurohormonal system modulation by vasopeptidase inhibitors--the novel therapeutical approach of hypertension treatment. | 2009 |
2 |
| 8 |
16086927 | Effect of angiotensin-converting enzyme or vasopeptidase inhibition on ventricular size and function in patients with heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE) echocardiographic study. | 2005 Aug |
1 |
| 9 |
16379325 | [Omapatrilat--new drug for patients with hypertension and heart failure]. | 2005 Oct |
1 |
| 10 |
14965315 | The shift in the "paradigm" of the pharmacology of hypertension. | 2004 |
1 |
| 11 |
14498755 | Dual ACE and neutral endopeptidase inhibitors: novel therapy for patients with cardiovascular disorders. | 2003 |
1 |
| 12 |
11827932 | Differential actions of vasopeptidase inhibition versus angiotensin-converting enzyme inhibition on diuretic therapy in experimental congestive heart failure. | 2002 Feb 5 |
2 |
| 13 |
11875587 | Vasopeptidase inhibition: a novel approach to cardiovascular therapy. | 2002 Feb |
2 |
| 14 |
12045365 | Omapatrilat provides long-term control of hypertension: a randomized trial of treatment withdrawal. | 2002 May-Jun |
1 |
| 15 |
12084605 | Vasopeptidase inhibition with omapatrilat in chronic heart failure: acute and long-term hemodynamic and neurohumoral effects. | 2002 Jun 19 |
3 |
| 16 |
12215465 | Renal hemodynamic and natriuretic effects of concomitant Angiotensin-converting enzyme and neutral endopeptidase inhibition in men. | 2002 Sep |
1 |
| 17 |
12239234 | Physiologic consequences of vasopeptidase inhibition in humans: effect of sodium intake. | 2002 Oct |
1 |
| 18 |
12584671 | Effects of the vasopeptidase inhibitor, omapatrilat, in 723 patients with coronary heart disease. | 2002 Dec |
1 |
| 19 |
11230840 | Effects of omapatrilat on systemic arterial function in patients with chronic heart failure. | 2001 Mar 1 |
1 |
| 20 |
11413936 | Effects of age and gender on the pharmacodynamics of omapatrilat in healthy volunteers. | 2001 Jan-Feb |
1 |
| 21 |
11564390 | Effects of omapatrilat on hemodynamics and safety in patients with heart failure. | 2001 Sep 15 |
1 |
| 22 |
11588409 | Advances in antihypertensive combination therapy: benefits of low-dose thiazide diuretics in conjunction with omapatrilat, a vasopeptidase inhibitor. | 2001 Sep-Oct |
2 |
| 23 |
11716802 | Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans. | 2001 Dec |
1 |
| 24 |
11751715 | Omapatrilat versus lisinopril: efficacy and neurohormonal profile in salt-sensitive hypertensive patients. | 2001 Dec 1 |
1 |
| 25 |
11890357 | Omapatrilat. Bristol-Myers Squibb. | 2001 Oct |
2 |
| 26 |
10856268 | In vitro and in vivo inhibition of the 2 active sites of ACE by omapatrilat, a vasopeptidase inhibitor. | 2000 Jun |
5 |
| 27 |
10933361 | The clinical, cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor, in patients with chronic heart failure. | 2000 Aug |
1 |
| 28 |
10968433 | Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. | 2000 Aug 19 |
2 |
| 29 |
11014407 | Disposition and safety of omapatrilat in subjects with renal impairment. | 2000 Sep |
1 |
| 30 |
11046097 | Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts. | 2000 Nov |
2 |
| 31 |
12845340 | Omapatrilat: clinical pharmacology. | 2000 Dec |
2 |
| 32 |
10340842 | Vasopeptidase inhibition: a new concept in blood pressure management. | 1999 Feb |
1 |